Methods of Cancer Diagnosis, Therapy, and Prognosis: Ovarian Cancer, Renal Cancer, Urogenitary tract Cancer, Urinary Bladder Cancer, Cervical Uterine Cancer, Skin Cancer, Leukemia, Multiple Myeloma an

ISBN-13: 9789048129171 / Angielski / Twarda / 2009 / 484 str.

M. A. Hayat

Opis

This volume presents a detailed survey of cancers. This volume was written by of various methodologies related to diag- 94 oncologists representing 13 countries. nosis, therapy, and prognosis of ovar- Their practical experience highlights their ian cancer, renal cancer, urinary bladder writings, which should build and further cancer, and cervical uterine cancer, while the endeavors of the readers in this imp- the already published Volumes 1 5 detail tant area of disease. The text of each c- similar aspects of breast, lung, prostate, cer type is divided into subheadings for liver, gastrointestinal, colorectal, and bil- the convenience of the readers. It is my iary tract carcinomas. hope that the current volume will join the It is well established that cancer is the preceding volumes of this series for assi- deadliest of human diseases. The follow- ing in the more complete understanding ing estimated global incidence of seven of globally relevant cancer syndromes. types of cancers discussed in this volume There exists a tremendous, urgent demand indicated the seriousness of this malig- by the public on the scientific community nancy. to address cancer prevention, diagnosis, treatment, and hopefully cures. Cervical uterine cancer 493,342 I am grateful to the contributors for their Urinary bladder cancer 357,000 promptness accepting my suggestions. I respect their dedication and diligent work Leukemia 300,522 in sharing their invaluable knowledge with Renal cancer 208,480 the public through this series."

Spis treści

PART I. OVARIAN CANCER Diagnosis 1. IDENTIFICATION OF BIOMARKERS FOR CLEAR CELL OVARIAN ADENOCARCINOMA; Samuel C. Mok, Michael P. Stanley, Hiroshi Tsuda, and Michael J. Birrer INTRODUCTION GENETIC ALTERATIONS IN CLEAR CELL OVARIAN CANCER CLEAR CELL OVARIAN CANCER HAS DISTINCT TRANSCRIPTION PROFILES DIFFERENTIAL GENE EXPRESSION IN CLEAR CELL ADENOCARCINOMA OF DIFFERENT ORGANS REFERENCES 2. OVARIAN CARCINOMA: DIAGNOSTIC IMMUNOHISTOCHEMISTRY OF MUCIN 4 (MUC4); Moorthy P. Ponnusamy, Ajay P. Singh, Subodh M. Lele, and Surinder K. Batra INTRODUCTION HISTOPATHOLOGY OF OVARIAN CANCER STAGES AND PROGNOSIS OF OVARIAN CANCER BIOMARKERS AND SCREENING OF OVARIAN CANCER ABERRANT MUCIN EXPRESSION IN OVARIAN CANCER MUCIN 4: Structure and Biology MUCIN 4 in Ovarian Cancer METHODOLOGY FOR MUCIN4 IMMUNOHISTOCHEMISTRY Tissue Sectioning Immunolabeling Assessment of MUC4 Staining REFERENCES 3. DISTINGUISHING BENIGN FROM MALIGNANT COMPLEX ADNEXAL MASSES IN OVARIAN CANCER: TWO- DIMENSIONAL POWER-DOPPLER IMAGING; Juan Luis Alcazar INTRODUCTION PATIENTS AND METHODS RESULTS DISCUSSION CONCLUSION REFERENCES 4. SUBGROUPS OF OVARIAN CARCINOMA: IDENTIFICATION USING DIFFERENTIAL GENE EXPRESSION; Kristin L.M. Boylan, Keith M. Skubitz, and Amy P.N. Skubitz INTRODUCTION OVARIAN CANCER HETEROGENEITY SELECTION OF SAMPLES FOR GENE MICROARRAY ANALYSIS CONTAMINATION OF GENE EXPRESSION PROFILES BY OTHER CELLS IN TISSUES NUMBER OF SAMPLES TO ANALYZE FOR GENE PROFILING IMPORTANCE OF PATHOLOGICAL QUALITY CONTROL CLINICAL CORRELATIONS GENE MICROARRAY PLATFORMS RNA ISOLATION FOR GENERATING GENE EXPRESSION DATA ANAYSIS OF GENE MICROARRAY DATA NEED FOR SECONDARY VALIDATION OF DATA GOALS FOR GENE MICROARRAY ANAYSIS GENE EXPRESSION ANALYSIS USED TO DETERMINE OVARIAN CANCER SUBGROUPS GENE EXPRESSION ANALYSIS USED TO COMPARE DIFFERENT STAGES OR GRADES OF OVARIAN CANCER GENE EXPRESSION PROFILES BASED ON METASTASIS CORRELATION OF GENE EXPRESSION PROFILES TO CHEMOTHERAPEUTIC RESPONSE CORRELATION OF GENE EXPRESSION PROFILES TO SURGICAL DEBULKING CORRELATION OF GENE EXPRESSION PROFILES TO PATIENTS’ SURVIVAL REFERENCES 5. SERTOLIFORM ENDOMETRIOID CARCINOMA OF THE OVARY: DIAGNOSIS AND PROGNOSIS; Monalisa Sur and Dean Daya INTRODUCTION DIAGNOSIS Clinical Features Gross Findings Microscopic Findings DIFFERENTIAL DIAGNOSIS IMMUNOHISTOCHEMISTRY Cytokeratins Epithelial Membrane Antigen Inhibin Calretinin Neural Cell Adhesion Molecule Estrogen and Progesterone Receptors Other Markers PROGNOSIS REFERENCES Prognosis 6. ROLE OF MUC16 (CA125) IN THE PATHOGENESIS OF EPITHELIAL OVARIAN CANCER; Jennifer A. Arens Gubbels, Joseph P. Connor, and Manish S. Patankar INTRODUCTION CA125 and MUC16 MUC16 in Epithelial Ovarian Cancer MESOTHELIN AND MUC16 BINDING: A MODEL FOR METASTASIS Mesothelin Mesothelin and MUC16 Binding Kinetics of Mesothelin-MUC16 Binding Mesothelin Binds to N-Linked Oligosaccharides Present on MUC16 MUC16 BINDING TO NATURAL KILLER CELLS: IMMUNOSUPPRESSIVE EFFECTS A Phenotypic Shift NK Cell Differentiation Tumor Cell Layers of Protection REFERENCES 7. CLEAR CELL CARCINOMA OF THE OVARY: PROGNOSIS USING CYTOREDUCTIVE SURGERY; Masashi Takano, Naoki Sasaki, and Toru Sugiyama INTRODUCTION CLINICAL CHARACTERISTICS MOLECULAR CHARACTERISTICS CLINICAL OUTCOME Resistance to

Blurb

This sixth volume in the series Methods of Cancer Diagnosis, Therapy, and Prognosis discusses Ovarian Cancer, Renal Cancer, Urogenitary Cancer, Urinary Bladder Cancer, Cervical Uterine Cancer, Skin Cancer, Leukemia, Multiple Myeloma and Sarcoma. Both standard and emerging therapies for these cancers, written by expert oncologists/pathologists in this field, are included.

This fully illustrated volume

• Identifies biomarkers based on genetic alterations for clear cell ovarian adenocarcinoma.
• Identifies subgroups of ovarian cancer by using differential gene expression.
• Includes the application of the power-Doppler imaging for distinguishing benign from malignant complex adrenal masses in ovarian cancer.
• Emphasizes the advantage of using cytoreduction surgery for diagnosing advanced ovarian cancer.
• Provides details on the treatment of kidney cancer with radiofrequency ablation, surgery, and chemotherapy.
• Explains the use of immunohistochemistry for diagnosing adenomatoid tumor of the adrenal gland.
• Discusses the chemotherapy of testicular cancer and related second primary tumors.
• Includes the diagnosis of urothelial bladder cancer with urine-based tumor markers.
• Explains the use of immunohistochemistry and MRI for diagnosing uterine cervical cancer and describes the staging of this cancer using PET alone or PET/CT.
• Describes the localization of malignant melanoma using FDG-PET/CT.
• Explains the use of prognostic receptors for nonmelanoma skin cancer.
• Details the treatment of multiple myeloma using immunotherapy, radiotherapy, and targeted radionuclide therapy.
• Presents diagnostic immunohistochemistry of synovial and Kaposi's sarcoma.

The technological advances presented in this volume are expected to expedite new discoveries and their translation to clinical practice. The field of oncology will benefit the most from these advanced methods, as a combination of therapies and personalized medicine will improve early detection of these different types of cancer.

Professor Hayat has summarized the problems associated with the complexities of research publications and has been successful in editing a must-read volume for oncologists, cancer researchers, medical teachers and students of cancer biology.